GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe ...

Following the promising multicentre, international Purpose 1 and Purpose 2 clinical trials with lenacapavir for HIV ...

The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

The Season 5 finale of The Handmaid's Tale left off on a truly wild cliffhanger, which is why the wait for new episodes has ...

According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...

While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...